MRK — Merck & Co., Inc.

Wall Street is clearly bullish: Q2 2026 revenue of $16.61B (+5% YoY) beat, guidance was raised to $65.8-67.0B, and the Aug 19, 2026 INTerpath-001 Phase 3 melanoma win with Moderna gave the first late-stage validation of an individualized mRNA cancer vaccine. Morgan Stanley, Wolfe, and UBS all raised targets to $175-180, and the stock is trading 28% above its 200-day moving average as of the analysis date.

Revenue has been stable-to-gently accelerating over the three-year window: quarterly sales mostly range between $15.6B and $17.2B, with YoY growth improving from roughly -1% in early 2025 to +3.2% in Sep-2025, +4.5% in Dec-2025, +4.3% in Mar-2026, and +5.1% in Jun-2026. Reported operating income turned negative in H1 2026 because of massive R&D charges ($12.6B in Q1 and $9.7B in Q2), which look like one-off/in-process R&D items rather than a collapse in the core business. Underlying operating margin is closer to 40%, and H1 2026 free cash flow of $7.4B more than doubled H1 2025, so this is an earnings blip, not a structural deterioration.

Headline valuation is distorted: TTM P/E of 118.7 and PEG of -1.5 are not meaningful because TTM EPS of $1.28 is depressed by the 2026 R&D charges. Normalizing earnings power to roughly $7.40 per share, the stock trades about 20x normalized EPS as of 2026-08-27. That is full for a mid-single-digit grower facing the 2028 Keytruda LOE, though the pipeline optionality and low beta justify a premium. P/S of 5.56 is above the 5-year average of 4.26, so the stock is not cheap, but the 2.92% dividend yield provides a reasonable floor.

As of 2026-08-27, the market is paying roughly 20x normalized earnings and 20.6x my normalized fair-value construct, meaning it is pricing in a successful post-Keytruda pipeline transition rather than just current Keytruda economics. The gap between the ugly trailing GAAP P/E and the healthier normalized P/E is the whole story: the market is looking through one-time charges and paying for Phase 3 mRNA data, Winrevair ramp, oral PCSK9, and Keytruda lifecycle management. If ESMO data and the PDUFA calendar deliver, the multiple can hold; any pipeline setback or LOE worry would compress it back toward high-teens.

As of 2026-08-27, RSI(14) is 64.55, which is strong but not yet overbought. Price is +7.9% above the 20-day, +14.3% above the 50-day, and +28.2% above the 200-day, so the trend is clearly up but short-term extended after the sharp YTD rally. The previous close was $153.10 and the stock ticked down 2.3% on the day, suggesting some consolidation risk; a pullback toward the 50-day would offer a more attractive entry.

• Keytruda U.S. loss of exclusivity in 2028 and biosimilar erosion remain the dominant long-term structural overhang.
• IRA/Medicare drug-price negotiation and broader U.S. pricing scrutiny create headline risk for large pharma.
• FDA approval cadence and compressed PDUFA calendar are now net-positive sentiment drivers for Merck.
• Low beta (0.21) and a 2.92% dividend yield make MRK a defensive/long-duration holding in a lower-rate or risk-off macro environment.
• Moderating FX volatility is reducing the currency drag on international revenues.

• ESMO October 23-27, 2026: full INTerpath-001 data plus a dedicated Merck investor event on October 26.
• Dense FDA PDUFA decisions in September-October 2026 could drive additional label expansions.
• Q3 2026 earnings on October 29, 2026, for updated guidance and commercial execution.
• Continued ramp of Winrevair, Lipfendra oral PCSK9, and Keytruda + Padcev in muscle-invasive bladder cancer.

• Keytruda LOE in 2028: if subcutaneous Keytruda and combo/lifecycle strategies fail to blunt biosimilar erosion, the revenue cliff is still real.
• Concentration risk: Merck remains heavily dependent on Keytruda, oncology, and a handful of newer launches.
• Balance sheet leverage is rising: long-term debt went from $34.0B in Jun-2025 to $51.1B in Jun-2026, while equity fell from $49.0B to $41.9B.
• Clinical/regulatory setbacks to the mRNA cancer vaccine or other pipeline assets would hit the premium multiple hardest.
• After a 45-50% YTD rally, the stock has less valuation cushion; any sentiment shift could cause a sharp de-rating.

Merck is a high-quality pharma business with improving momentum, and the "Good Fundamentals" score is a fair read of trailing data. The stock is no longer cheap after the YTD run, but the positive INTerpath-001 readout and broad pipeline materially reduce the post-2028 risk, so the risk/reward remains constructive. Directionally bullish, with the caveat that entry timing matters after such a sharp move.

I calculated roughly $7.40 of normalized EPS using TTM revenue of $66.4B, a normalized operating margin near 40%, the 2025 operating-income-to-net-income conversion rate of ~68%, and about 2.47B shares outstanding. I then applied a 20.6x P/E multiple—a premium to large pharma for pipeline optionality, low beta, and the dividend, but constrained by mid-single-digit growth and the 2028 Keytruda LOE—resulting in a fair value of approximately $152.50 as of 2026-08-27.